The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Targeting CD47 in myelofibrosis
Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, talks on the role of CD47 and CALR in myelofibrosis (MF) and comments on the potential of targeting CD47 in MF. It has been shown that patients with MF overexpress CD47, an anti-phagocytic receptor, and have a lower expression of CALR, a pro-phagocytic molecule, which results in a dominant anti-phagocytic signal. Recent in vitro assays have shown that treatment with ruxolitinib and magrolimab, a monoclonal antibody against CD47, led to increased cell death. This interview took place virtually.
